<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890199</url>
  </required_header>
  <id_info>
    <org_study_id>HHC-2016-0169</org_study_id>
    <nct_id>NCT02890199</nct_id>
  </id_info>
  <brief_title>Effect of Local Anesthesia on Postoperative Pain Following Sacrospinous Ligament Fixation</brief_title>
  <official_title>Effect of Local Anesthesia on Postoperative Pain Following Sacrospinous Ligament Fixation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Association of Gynecologic Laparoscopists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hartford Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During surgery for pelvic organ prolapse, it is common for the surgeon to inject fluid into
      the vaginal tissues to help with tissue dissection. It is common that anesthetic medication
      is mixed into this fluid to help with pain control after surgery. Usually the pain medication
      injected is short-acting. In this study the investigators plan to compare the usual
      short-acting injected pain medication with a long-acting injected pain medication to evaluate
      whether this improves pain control after surgery.

      One type surgical procedure for prolapse will be evaluated. The procedure is sacrospinous
      ligament fixation. This is suspension of the vagina to treat pelvic organ prolapse. Study
      participants will be randomized to one of two study groups:

        1. Lidocaine group (short-acting medication).

        2. Liposomal bupivacaine group (long-acting medication)

      Information will be collected on study participants, including: demographics, procedure data,
      and post-operative information. The primary outcome of this study is determine if use of
      long-acting injected local anesthesia at the time of sacrospinous ligament fixation leads to
      less post-operative pain compared to short-acting local anesthesia.

      Secondary outcomes include:

        1. post-operative opioid medication use

        2. return to baseline pain status

        3. post-operative time to first bowel movement

        4. post-operative antiemetic use (nausea medication)

        5. results of voiding trial after surgery

        6. patient satisfaction with pain control
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog pain scale</measure>
    <time_frame>1 to 120 hours post-operative</time_frame>
    <description>post-operative pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Equivalents of morphine used for pain control post-operative while hospitalized</measure>
    <time_frame>1-2 days post-operative</time_frame>
    <description>Post-operative opioid use, in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equivalents of morphine used from the time of hospital discharge to post-operative day 7</measure>
    <time_frame>7 days post-operative</time_frame>
    <description>Post-operative opioid use, after hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified surgical pain scale</measure>
    <time_frame>3, 7, 14, 28 days post-operative</time_frame>
    <description>Return to baseline pain status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first bowel movement</measure>
    <time_frame>1-28 days post-operative</time_frame>
    <description>Days to first postoperative bowel movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative antiemetic use, in hospital</measure>
    <time_frame>1-2 days post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Void trial</measure>
    <time_frame>1-2 days post-operative</time_frame>
    <description>Results of in-hospital void trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCHAPS pain questionnaire</measure>
    <time_frame>48 hours post-operative</time_frame>
    <description>Patient satisfaction with pain control</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>Lidocaine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.5% lidocaine mixed with 1:200,000 epinephrine 70 milliliters (mL) will be used for local injection at the sacrospinous ligament and for anterior / posterior colporrhaphy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine liposomal group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.3% bupivacaine liposomal (20 mL) injected at the sacrospinous ligament 0.5% lidocaine mixed with 1:200,000 epinephrine 50mL for the anterior / posterior colporrhaphy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine liposomal</intervention_name>
    <arm_group_label>Bupivacaine liposomal group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>Lidocaine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female gender

          2. Age ≥ 18 years, ≤95 years

          3. Planned vaginal sacrospinous ligament fixation with anterior and/or posterior
             colporrhaphy (SSLF APC) to treat pelvic organ prolapse with or without retropubic mid
             urethral sling

          4. Able to give informed consent to participate

        Exclusion Criteria:

          1. Male

          2. Age &lt;18 years, &gt; 95 years

          3. Unable or unwilling to give informed consent to participate

          4. Pregnancy

          5. History of chronic pelvic pain, narcotic abuse, or daily narcotic usage in the last
             six months

          6. Known allergy / intolerance to either lidocaine, bupivacaine liposomal, ketorolac,
             motrin, or acetaminophen

          7. Known renal or hepatic insufficiency

          8. Planned hysterectomy at the time of prolapse repair

          9. Planned transobturator mid urethral sling at the time of prolapse repair
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Propst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie Propst, MD</last_name>
    <phone>860-972-4338</phone>
    <email>katie.propst@hhchealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David M. O'Sullivan, PhD</last_name>
    <email>david.o'sullivan@hhchealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Hospital, Urogynecology Division</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Propst, MD</last_name>
      <phone>860-972-4338</phone>
      <email>katie.propst@hhchealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hartford Hospital</investigator_affiliation>
    <investigator_full_name>Katie Propst</investigator_full_name>
    <investigator_title>Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

